YSS · York Space Systems Inc. · Stock research

7# YSS York Space Systems, Inc.

Current Thesis

The roll-up-execution leg that framed this name through May and June is gone. YSS closed at $17.93 on 2026-07-17, roughly 45% below the January IPO range of $30–$34 and within 6% of the $16.93 52-week low, against a 52-week high of $44.54. Both acquisitions the prior read was waiting on actually closed ALL.SPACE on 2026-07-08 for $300M ($155M cash plus 5.9M shares) and Solestial for roughly $67M including 1,703,577 shares and the tape did not care. That is the signal. When a company delivers the exact catalysts it promised and the stock makes new lows into the news, the market is pricing something the press releases do not address: Wolfpack Research's 2026-05-12 claim that the Pentagon's cancellation of the SDA Tranche 3 Transport Layer removes the program behind 96% of last year's revenue. Q1 gave that thesis partial corroboration gross margin down four points year over year on negative estimate-at-completion adjustments, revenue slipping into Q3 and Q4, a $1.51 per-share loss and five separate law firms have since opened securities investigations into whether management accurately disclosed contract delivery status. The nearest dated event is the ~2026-07-28 IPO lock-up expiry, which adds supply to a broken chart. This is a falling knife with a supply catalyst in front of it.

Bullish and bearish views on York Space Systems Inc.

The model's bull view on York Space Systems Inc. (YSS), in brief: Both announced deals closed on time: ALL.SPACE 2026-07-08 ($300M, 5.9M shares + $155M cash) and Solestial (~$67M, 1,703,577 shares), removing the financing and reprice overhang the June read flagged. The bear view: The core revenue base is under direct attack: Wolfpack's 2026-05-12 report ("Lost In Space") ties 96% of FY25 revenue to an SDA program the Pentagon moved to dissolve, with the replacement built around SpaceX as sole source. Both cases follow in full.

Bull Case

• Both announced deals closed on time: ALL.SPACE 2026-07-08 ($300M, 5.9M shares + $155M cash) and Solestial (~$67M, 1,703,577 shares), removing the financing and reprice overhang the June read flagged.
• Jefferies reinstated Buy with a $32 target on 2026-07-13, estimating ALL.SPACE adds ~$20M in annual revenue against a $565M FY26 estimate a firm underwriting the story after the short report, not before it.
• Sell-side has not capitulated: 8 buys, 3 holds, 1 sell across 12 analysts, consensus target $34.89 as of 2026-07-17.
• Hardware is shipping: the second production lot of SDA Transport Layer communications satellites was declared launch-ready 2026-07-15, and the Dragoon mission met its objectives difficult to reconcile with a pure vaporware short thesis.
• Revenue is still compounding: TTM sales $396.29M, +66.4% year over year, with Q1 sales of $116.343M beating the $109.588M estimate on 2026-05-14.
• Short interest fell to 6.26% of float, down 9.1% month over month the crowded-short setup has partially cleared, meaning the decline since May is real selling rather than short pressure alone.

Bear Case

• The core revenue base is under direct attack: Wolfpack's 2026-05-12 report ("Lost In Space") ties 96% of FY25 revenue to an SDA program the Pentagon moved to dissolve, with the replacement built around SpaceX as sole source. Two months later the report is unrefuted.
• Every structural level from the prior $31–$33 analyst cluster down has been lost on a weekly basis.
• Q1 quality was poor beneath the headline beat: gross margin -4pp year over year on negative EAC adjustments, revenue deferred to Q3/Q4, a -$1.51 EPS miss, and TTM net income of -$249.11M.
• Five securities-law investigations are now open Johnson Fistel (2026-05-18), Kirby McInerney (2026-05-19), Pomerantz, and Lowey Dannenberg (2026-06-30 and again 2026-07-16) the last specifically probing disclosures on defense-technology maturity and true spacecraft delivery status.
• The ~2026-07-28 lock-up expiry (180 days from the 2026-01-28 prospectus) releases insider and pre-IPO holders into a stock trading ~45% below its IPO price. Holders underwater since day one still hold shares worth far more than zero.
• A consensus target of $34.89 sits ~95% above spot. A gap that wide on a name making new lows means the analyst models have not been marked to the SDA news, and the revisions ahead are downward.
• The 7.6M-plus shares issued for the two acquisitions dilute a 129.69M-share count into a declining tape.

Setup & Price Structure

Structurally broken with no evidence of a base. The stock closed 2026-07-17 at $17.93, down 3.24% on the session, sitting 4.6% above the 52-week low of $16.93 and 60% below the $44.54 high. The $31–$33 analyst-target shelf that anchored the prior framework was lost outright and has not been retested. Market cap is $2.33B on 129.69M shares. There is no higher low, no reclaimed moving average, and no volume shelf visible in the decline the pattern is a persistent downtrend punctuated by news-driven gaps lower. Buying here on the argument that "the deals closed and it's cheaper than it was" is the definition of catching a name below every reference level, and adding on further weakness would compound it. The relevant question is not valuation but whether the SDA revenue base survives, and price is voting no. A constructive setup requires the stock to first stop making lower lows, then reclaim and hold prior resistance on a weekly basis neither condition is close.

Catalyst Calendar (next 30 days)

• ~2026-07-28 IPO lock-up expiry (180 days from the 2026-01-28 final prospectus). Insider and pre-IPO supply becomes free to sell into a chart at 52-week lows. Primary near-term event.
• ~2026-08-13 (est.) Q2 FY26 print, extrapolated from the 2026-05-14 Q1 release. The first hard test of whether the SDA Tranche 3 cancellation has flowed into backlog, guidance, and the FY26 $545M–$595M range. Binary; avoid fresh entries into it.
• Ongoing, undated any formal management rebuttal to the Wolfpack report, or a new prime contract that visibly replaces SDA revenue.

Elapsed catalysts

• Ongoing, undated securities-investigation escalation. Lowey Dannenberg's second announcement came 2026-07-16; a filed class action or an SEC inquiry would be a step-change, not an incremental headline. _(passed 3d ago)_
• Ongoing, undated SDA Transport Layer launch for the second production lot declared ready 2026-07-15. A successful launch is the cleanest available rebuttal to the execution half of the short thesis. _(passed 4d ago)_

What Would Change Our Mind

The bear case dies on evidence, not on price. The specific things that would rebuild a case: a Q2 print in mid-August that holds the FY26 $545M–$595M guide with backlog detail explicitly quantifying non-SDA revenue; a new large program award that demonstrably replaces the Tranche 3 revenue line; a detailed, itemized management rebuttal to Wolfpack rather than silence; and, on the chart, the lock-up date passing without a break of $16.93 followed by a weekly close back above the prior breakdown shelf on expanding volume. Absent that sequence, the reasonable stance is to stand aside and let the ~2026-07-28 supply event and the mid-August print clear first. Cheapness relative to the January IPO price is not a thesis the IPO priced a revenue base the Pentagon has since moved to eliminate.

Correlation Notes

Space-economy peers (RKLB and the broader launch/satellite complex) have decoupled from YSS since May; this is idiosyncratic damage, not sector beta, so a strong tape in space names offers no rescue here. Defense-budget exposure cuts against the position rather than for it the SDA restructuring toward a SpaceX sole-source architecture is a share-shift within a growing budget, and YSS is on the losing side of it. The name now trades more like a post-short-report litigation special situation than a defense-infrastructure compounder, meaning the drivers are legal calendar, insider supply, and one quarterly disclosure event rather than industry demand. Cross-read to watch: any SpaceX/Starshield contract news, which is directly the other side of the same trade.